Form 4: Rhythm Pharma CAO Exercises Options, Sells Shares
Insider Transaction Report
Rhythm Pharmaceuticals' Corporate Controller and CAO, Christopher Paul German, executed pre-planned transactions involving the exercise of stock options and subsequent sale of common stock.
Summary
- Christopher Paul German, Corporate Controller & CAO of Rhythm Pharmaceuticals, Inc. (RYTM), reported transactions on August 12, 2025.
- German acquired 1,000 shares of common stock by exercising stock options at a price of $17.97 per share.
- An additional 500 shares of common stock were acquired through the exercise of stock options at a price of $49.23 per share.
- Following these acquisitions, German disposed of 1,500 shares of common stock at a price of $95.00 per share.
- The sale of shares was conducted pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2025.
- After these transactions, German's direct beneficial ownership of common stock is 922 shares.
- The stock options exercised were granted on April 4, 2023, and February 16, 2024, with specific vesting schedules.
Sentiment
Score: 6
Explanation: The sentiment is slightly positive. While an insider sale can sometimes be viewed negatively, this transaction was pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling. The insider also realized significant profits from exercising options, which is a positive for the individual.
Positives
- The exercise of stock options indicates the insider is realizing value from their equity compensation.
- The sale price of $95.00 per share is significantly higher than the exercise prices of $17.97 and $49.23, indicating a substantial profit for the reporting person.
Negatives
- The sale of 1,500 shares by a key executive reduces their direct ownership in the company.
Future Outlook
NA
Industry Context
This filing is a routine insider transaction report for a pharmaceutical company. It does not provide broader industry trends or competitive analysis.
Stakeholder Impact
- Shareholders: The sale of shares by a key executive, even if pre-planned, slightly reduces insider ownership. However, the pre-planned nature minimizes negative signaling.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2023-04-04 | Grant date for stock options with an exercise price of $17.97. |
| 2024-02-16 | Grant date for stock options with an exercise price of $49.23. |
| 2024-03-20 | First vesting date (25%) for stock options granted on April 4, 2023. |
| 2024-06-20 | Start of quarterly vesting installments for stock options granted on April 4, 2023. |
| 2025-03-11 | Date Rule 10b5-1 trading plan was adopted by the Reporting Person. |
| 2025-08-12 | Transaction date for stock option exercises and common stock sale. |
| 2025-08-14 | Date the Form 4 was signed. |
| 2027-03-20 | End date for quarterly vesting installments for stock options granted on April 4, 2023. |
| 2033-04-03 | Expiration date for stock options with an exercise price of $17.97. |
| 2034-02-15 | Expiration date for stock options with an exercise price of $49.23. |
Keywords
Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Trading, Stock Options, Equity Compensation, Rule 10b5-1 Plan, Corporate Controller, CAO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.